Crescent Capital (CCAP) 10% owner offloads 73K shares

Fidelity & Guaranty Life Insurance Co, a 10% owner of Crescent Capital BDC (CCAP), sold 73,457 shares of common stock in two transactions on 2026-08-24 and 2026-08-25. The sales, executed under a Rule 10b5-1 trading plan, were at average prices of $10.72–$10.80 per share, totaling approximately $788,000.

Original reporting
Published Aug 26, 2026, 7:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CCAP
Neutral
high confidence
Mentioned
$CCAP
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CCAPNeutralLow
01

Why it matters

Routine insider transaction with limited market impact; serves as a compliance disclosure.

02

Market read

Low relevance; informs investors of a modest insider sell but unlikely to move the stock.

03

What to watch

Potential tax‑loss harvesting or portfolio rebalancing by the insurer.

Relevance 4/10Novelty 4/10Timing: post‑market 2026-08-25

Background

Form 4 filing by a 10% owner disclosing open‑market sales under a 10b5‑1 plan.

Company-level read

Ticker impact

$CCAPNeutralHigh confidence
Context

10% owner Fidelity & Guaranty Life sold 73,457 CCAP shares on 2026-08-24/25 under a Rule 10b5‑1 plan.

Expected impact

Minimal short‑term impact; price may dip marginally.

Evidence & confidence

Sale size is modest relative to float and executed via pre‑arranged plan, limiting informational content.

Market effects

None; BDC sector unchanged.

None; limited to CCAP shareholders.

None

Counterpoint

The sale could be a signal of upcoming negative news not yet disclosed.

Key entities

  • Crescent Capital BDC, Inc.

    US‑listed BDC (ticker CCAP).

  • Fidelity & Guaranty Life Insurance Co.

    10% shareholder reporting the sale.

Related articles

$CCAPHigh

Crescent Capital Q3 2026 slides: earnings beat, $50M buyback unveiled

Crescent Capital BDC (CCAP) reported Q3 2026 earnings of $0.37 per share, beating estimates. The company announced a $50M share buyback and a joint venture to reduce leverage. Shares rose 6.82% in after-hours trading to $9.87, still below NAV. Portfolio assets reached $1.6B, with 91% in senior secured positions. Net investment income declined year-over-year, and NAV per share fell 8%.

$CCAPMed

Crescent Capital BDC, Inc. Reports Third Quarter 2026 Earnings Results

Crescent Capital BDC, Inc. (CCAP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Capital BDC, Inc. Reports Third Quarter 2026 Earnings Results; Declares a Fourth Quarter Base Dividend of $0.34 Per Share and Announces a $50 Million Share Repurchase Program LOS ANGELES, November 9, 2026 — Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ

$CCAPMed

Crescent Capital BDC, Inc. Reports Second Quarter 2026 Earnings Results

Crescent Capital BDC, Inc. (CCAP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Capital BDC, Inc. Reports Second Quarter 2026 Earnings Results; Declares a Third Quarter Base Dividend of $0.34 Per Share LOS ANGELES, August 10, 2026 — Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $0.36

$LQDAMed

BTIG raises Liquidia stock price target to $87 on strong demand

BTIG raised its price target for Liquidia Technologies (LQDA) to $87 from $70, citing strong demand for Yutrepia and increased 2027 EPS estimates. LQDA's Q3 revenue beat expectations at $225.3M, with Yutrepia sales up 31%, though GAAP EPS loss was $2.64 due to a $389.7M settlement charge. Jefferies also raised its target to $62, maintaining a Buy rating.